Taylor H R, Semba R D, Newland H S, Keyvan-Larijani E, White A, Dukuly Z, Greene B M
Johns Hopkins University, Baltimore, Maryland.
Am J Trop Med Hyg. 1989 May;40(5):494-500. doi: 10.4269/ajtmh.1989.40.494.
The treatment of onchocerciasis with diethylcarbamazine and suramin is associated with an exacerbation of ocular disease. This occurs more frequently in patients with severe onchocercal ocular disease. We assessed ocular changes following ivermectin treatment in 39 patients with severe ocular onchocerciasis. Patients were treated with 100, 150, or 200 micrograms/kg of ivermectin at either 1 or 2 year intervals and followed for 3 years. There was no evidence for an acute exacerbation of either anterior or posterior segment eye disease, and there was a marked improvement in ocular status in the group as a whole. There was a significant decrease in onchocercal involvement which was maintained for at least 3 years. Annual treatment with ivermectin can be used safely in patients with severe ocular disease and is beneficial over a prolonged period of time.
用乙胺嗪和苏拉明治疗盘尾丝虫病与眼部疾病的加重有关。这种情况在患有严重盘尾丝虫性眼病的患者中更频繁地发生。我们评估了39例严重眼部盘尾丝虫病患者接受伊维菌素治疗后的眼部变化。患者每隔1年或2年接受100、150或200微克/千克的伊维菌素治疗,并随访3年。没有证据表明前段或后段眼病有急性加重,并且整个组的眼部状况有明显改善。盘尾丝虫感染明显减少,这种情况至少维持了3年。对于患有严重眼部疾病的患者,每年使用伊维菌素治疗是安全的,并且在较长时期内是有益的。